Search

Your search keyword '"van der Burg, Sjoerd H"' showing total 1,245 results
Start Over Author "van der Burg, Sjoerd H"
1,245 results on '"van der Burg, Sjoerd H"'

2. T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors

Author

Middelburg, Jim, Sluijter, Marjolein, Schaap, Gaby, Göynük, Büşra, Lloyd, Katy, Ovcinnikovs, Vitalijs, Zom, Gijs G., Marijnissen, Renoud J., Groeneveldt, Christianne, Griffioen, Lisa, Sandker, Gerwin G. W., Heskamp, Sandra, van der Burg, Sjoerd H., Arakelian, Tsolere, Ossendorp, Ferry, Arens, Ramon, Schuurman, Janine, Kemper, Kristel, and van Hall, Thorbald

Published
2024
Full Text
View/download PDF

5. Inhibiting the NADase CD38 improves cytomegalovirus-specific [CD8.sup.+] T cell functionality and metabolism

Author

Mulling, Nils, Behr, Felix M., Heieis, Graham A., Boss, Kristina, van Duikeren, Suzanne, van Haften, Floortje J., Pardieck, Iris N., van der Gracht, Esme T.I., Vleeshouwers, Ward, van der Sluis, Tetje C., de Graaf, J. Frederique, Veerkamp, Dominique M.B., Franken, Kees L.M.C., Lei, Xin, van de Sand, Lukas, van der Burg, Sjoerd H., Welters, Marij J.P., Heidt, Sebastiaan, Huisman, Wesley, Jochems, Simon P., Giera, Martin, Witzke, Oliver, de Vries, Aiko P.J., Kribben, Andreas, Everts, Bart, Wilde, Benjamin, and Arens, Ramon

Subjects
Physiological aspects, Health aspects, CD8 lymphocytes -- Health aspects, Glycoproteins -- Health aspects, Medical research, Metabolism -- Health aspects, Cytomegalovirus infections -- Physiological aspects, Medicine, Experimental
Abstract

Introduction Human cytomegalovirus (CMV) is one of the most encountered opportunistic viral pathogens in kidney transplant recipients (KTRs) (1). Although major advances in the treatment and prophylaxis of CMV-associated complications [...], Cytomegalovirus (CMV) is one of the most common and relevant opportunistic pathogens in people who are immunocompromised, such as kidney transplant recipients (KTRs). The exact mechanisms underlying the disability of cytotoxic T cells to provide sufficient protection against CMV in people who are immunosuppressed have not been identified yet. Here, we performed in-depth metabolic profiling of CMV-specific [CD8.sup.+] T cells in patients who are immunocompromised and show the development of metabolic dysregulation at the transcriptional, protein, and functional level of CMV-specific [CD8.sup.+] T cells in KTRs with noncontrolled CMV infection. These dysregulations comprise impaired glycolysis and increased mitochondrial stress, which is associated with an intensified expression of the nicotinamide adenine dinucleotide nucleotidase (NADase) CD38. Inhibiting NADase activity of CD38 reinvigorated the metabolism and improved cytokine production of CMV-specific [CD8.sup.+] T cells. These findings were corroborated in a mouse model of CMV infection under conditions of immunosuppression. Thus, dysregulated metabolic states of [CD8.sup.+] T cells could be targeted by inhibiting CD38 to reverse hyporesponsiveness in individuals who fail to control chronic viral infection.

Published
2024
Full Text
View/download PDF

9. Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment

Author

Haake, Markus, Haack, Beatrice, Schäfer, Tina, Harter, Patrick N., Mattavelli, Greta, Eiring, Patrick, Vashist, Neha, Wedekink, Florian, Genssler, Sabrina, Fischer, Birgitt, Dahlhoff, Julia, Mokhtari, Fatemeh, Kuzkina, Anastasia, Welters, Marij J. P., Benz, Tamara M., Sorger, Lena, Thiemann, Vincent, Almanzar, Giovanni, Selle, Martina, Thein, Klara, Späth, Jacob, Gonzalez, Maria Cecilia, Reitinger, Carmen, Ipsen-Escobedo, Andrea, Wistuba-Hamprecht, Kilian, Eichler, Kristin, Filipski, Katharina, Zeiner, Pia S., Beschorner, Rudi, Goedemans, Renske, Gogolla, Falk Hagen, Hackl, Hubert, Rooswinkel, Rogier W., Thiem, Alexander, Roche, Paula Romer, Joshi, Hemant, Pühringer, Dirk, Wöckel, Achim, Diessner, Joachim E., Rüdiger, Manfred, Leo, Eugen, Cheng, Phil F., Levesque, Mitchell P., Goebeler, Matthias, Sauer, Markus, Nimmerjahn, Falk, Schuberth-Wagner, Christine, von Felten, Stefanie, Mittelbronn, Michel, Mehling, Matthias, Beilhack, Andreas, van der Burg, Sjoerd H., Riedel, Angela, Weide, Benjamin, Dummer, Reinhard, and Wischhusen, Jörg

Published
2023
Full Text
View/download PDF

10. The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent

Author

Middelburg, Jim, Ghaffari, Soroush, Schoufour, Tom A.W., Sluijter, Marjolein, Schaap, Gaby, Göynük, Büsra, Sala, Benedetta M., Al-Tamimi, Lejla, Scheeren, Ferenc, Franken, Kees L.M.C., Akkermans, Jimmy J.L.L., Cabukusta, Birol, Joosten, Simone A., Derksen, Ian, Neefjes, Jacques, van der Burg, Sjoerd H., Achour, Adnane, Wijdeven, Ruud H.M., Weidanz, Jon, and van Hall, Thorbald

Published
2023
Full Text
View/download PDF

13. Challenges in neoantigen-directed therapeutics

Author

Lybaert, Lien, Lefever, Steve, Fant, Bruno, Smits, Evelien, De Geest, Bruno, Breckpot, Karine, Dirix, Luc, Feldman, Steven A., van Criekinge, Wim, Thielemans, Kris, van der Burg, Sjoerd H., Ott, Patrick A., and Bogaert, Cedric

Published
2023
Full Text
View/download PDF

14. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma* [S]

Author

Shraibman, Bracha, Barnea, Eilon, Kadosh, Dganit Melamed, Haimovich, Yael, Slobodin, Gleb, Rosner, Itzhak, López-Larrea, Carlos, Hilf, Norbert, Kuttruff, Sabrina, Song, Colette, Britten, Cedrik, Castle, John, Kreiter, Sebastian, Frenzel, Katrin, Tatagiba, Marcos, Tabatabai, Ghazaleh, Dietrich, Pierre-Yves, Dutoit, Valérie, Wick, Wolfgang, Platten, Michael, Winkler, Frank, von Deimling, Andreas, Kroep, Judith, Sahuquillo, Juan, Martinez-Ricarte, Francisco, Rodon, Jordi, Lassen, Ulrik, Ottensmeier, Christian, van der Burg, Sjoerd H, Thor Straten, Per, Poulsen, Hans Skovgaard, Ponsati, Berta, Okada, Hideho, Rammensee, Hans-Georg, Sahin, Ugur, Singh, Harpreet, and Admon, Arie

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Clinical Research, Rare Diseases, Brain Disorders, Neurosciences, Brain Cancer, Cancer, Good Health and Well Being, Alleles, Antigens, Neoplasm, Biomarkers, Tumor, Brain Neoplasms, Glioblastoma, Histocompatibility Antigens Class I, Humans, Peptides, Proteome, CTA, Cancer Biomarker(s), Cancer Therapeutics, HLA, Immunoaffinity, Immunotherapy, MHC, Peptidomics, Plasma or Serum Analysis, Biochemistry & Molecular Biology
Abstract

Glioblastoma multiforme (GBM) is the most aggressive brain tumor with poor prognosis to most patients. Immunotherapy of GBM is a potentially beneficial treatment option, whose optimal implementation may depend on familiarity with tumor specific antigens, presented as HLA peptides by the GBM cells. Further, early detection of GBM, such as by a routine blood test, may improve survival, even with the current treatment modalities. This study includes large-scale analyses of the HLA peptidome (immunopeptidome) of the plasma-soluble HLA molecules (sHLA) of 142 plasma samples, and the membranal HLA of GBM tumors of 10 of these patients' tumor samples. Tumor samples were fresh-frozen immediately after surgery and the plasma samples were collected before, and at multiple visits after surgery. In total, this HLA peptidome analysis involved 52 different HLA allotypes and resulted in the identification of more than 35,000 different HLA peptides. Strong correlations were observed in the signal intensities and in the repertoires of identified peptides between the tumors and plasma-soluble HLA peptidomes of the individual patients, whereas low correlations were observed between these HLA peptidomes and the tumors' proteomes. HLA peptides derived from Cancer/Testis Antigens (CTAs) were selected based on their presence among the HLA peptidomes of the patients and absence of expression of their source genes from any healthy and essential human tissues, except from immune-privileged sites. Additionally, peptides were selected as potential biomarkers if their levels in the plasma-sHLA peptidome were significantly reduced after the removal of tumor mass. The CTAs identified among the analyzed HLA peptidomes provide new opportunities for personalized immunotherapy and for early diagnosis of GBM.

Published
2019

22. Figure S15 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies

Author

Groeneveldt, Christianne, primary, Kinderman, Priscilla, primary, Griffioen, Lisa, primary, Rensing, Olivia, primary, Labrie, Camilla, primary, van den Wollenberg, Diana J.M., primary, Hoeben, Rob C., primary, Coffey, Matt, primary, Loghmani, Houra, primary, Verdegaal, Els M.E., primary, Welters, Marij J.P., primary, van der Burg, Sjoerd H., primary, van Hall, Thorbald, primary, and van Montfoort, Nadine, primary

Published
2024
Full Text
View/download PDF

23. Data from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies

Author

Groeneveldt, Christianne, primary, Kinderman, Priscilla, primary, Griffioen, Lisa, primary, Rensing, Olivia, primary, Labrie, Camilla, primary, van den Wollenberg, Diana J.M., primary, Hoeben, Rob C., primary, Coffey, Matt, primary, Loghmani, Houra, primary, Verdegaal, Els M.E., primary, Welters, Marij J.P., primary, van der Burg, Sjoerd H., primary, van Hall, Thorbald, primary, and van Montfoort, Nadine, primary

Published
2024
Full Text
View/download PDF

24. Supplementary Tables S1-S3 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies

Author

Groeneveldt, Christianne, primary, Kinderman, Priscilla, primary, Griffioen, Lisa, primary, Rensing, Olivia, primary, Labrie, Camilla, primary, van den Wollenberg, Diana J.M., primary, Hoeben, Rob C., primary, Coffey, Matt, primary, Loghmani, Houra, primary, Verdegaal, Els M.E., primary, Welters, Marij J.P., primary, van der Burg, Sjoerd H., primary, van Hall, Thorbald, primary, and van Montfoort, Nadine, primary

Published
2024
Full Text
View/download PDF

25. Dendritic Cell–Based Immunotherapy in Patients With Resected Pancreatic Cancer

Author

van't Land, Freek R., Willemsen, Marcella, Bezemer, Koen, van der Burg, Sjoerd H., van den Bosch, Thierry P.P., Doukas, Michail, Fellah, Amine, Kolijn, P. Martijn, Langerak, Anton W., Moskie, Miranda, van der Oost, Elise, Rozendaal, Nina E.M., Baart, Sara J., Aerts, Joachim G.J.V., van Eijck, Casper H.J., van't Land, Freek R., Willemsen, Marcella, Bezemer, Koen, van der Burg, Sjoerd H., van den Bosch, Thierry P.P., Doukas, Michail, Fellah, Amine, Kolijn, P. Martijn, Langerak, Anton W., Moskie, Miranda, van der Oost, Elise, Rozendaal, Nina E.M., Baart, Sara J., Aerts, Joachim G.J.V., and van Eijck, Casper H.J.

Abstract

PURPOSE:Immunotherapies have shown limited responses in patients with advanced pancreatic cancer. Recently, we reported that dendritic cell (DC)–based immunotherapy induced T-cell responses against pancreatic cancer antigens. The primary objective of this study was to determine the efficacy of DC-based immunotherapy to prevent recurrence of disease.METHODS: This was a single-center, open-label, single-arm, combined phase I/II trial. The primary end point was the 2-year recurrence-free survival (RFS) rate. A 2-year RFS rate of ≥60% was defined as a clinically meaningful improvement. We included patients with pancreatic cancer after resection and completion of standard-of-care (SOC) treatment without recurrent disease on cross-sectional imaging. Patients were treated with autologous DCs pulsed with an allogeneic mesothelioma tumor cell lysate, comprising antigens also expressed in pancreatic ductal adenocarcinoma. RESULTS: Thirty-eight patients were included in the analysis of the primary end point (47% male, 53% female). The median age was 62 years (IQR, 55-68). Twenty-eight patients (74%) received five DC vaccinations and completed the study protocol. Three patients (8%) received four vaccinations, and seven patients (16%) received three vaccinations. After a median follow-up of 25.5 months, 26 patients (68%) had not developed recurrence of disease. The estimated 2-year RFS was 64%. Vaccination led to the enrichment of circulating activated CD41 T cells and the detection of treatment-induced immune responses in vitro. T-cell receptor-sequencing analyses of a resected solitary lung metastasis showed influx of vaccine-specific T cells.CONCLUSION: This study reached its primary end point of a 2-year RFS rate of ≥60% following pancreatectomy after SOC treatment and adjuvant DC-based immunotherapy in patients with pancreatic cancer. These results warrant a future randomized trial.

Published
2024

27. Consensus nomenclature for CD8+ T cell phenotypes in cancer

Author

Apetoh, Lionel, Smyth, Mark J, Drake, Charles G, Abastado, Jean-Pierre, Apte, Ron N, Ayyoub, Maha, Blay, Jean-Yves, Bonneville, Marc, Butterfield, Lisa H, Caignard, Anne, Castelli, Chiara, Cavallo, Federica, Celis, Esteban, Chen, Lieping, Colombo, Mario P, Comin-Anduix, Begoña, Coukos, Georges, Dhodapkar, Madhav V, Dranoff, Glenn, Frazer, Ian H, Fridman, Wolf-Hervé, Gabrilovich, Dmitry I, Gilboa, Eli, Gnjatic, Sacha, Jäger, Dirk, Kalinski, Pawel, Kaufman, Howard L, Kiessling, Rolf, Kirkwood, John, Knuth, Alexander, Liblau, Roland, Lotze, Michael T, Lugli, Enrico, Marincola, Francesco, Melero, Ignacio, Melief, Cornelis J, Mempel, Thorsten R, Mittendorf, Elizabeth A, Odun, Kunle, Overwijk, Willem W, Palucka, Anna Karolina, Parmiani, Giorgio, Ribas, Antoni, Romero, Pedro, Schreiber, Robert D, Schuler, Gerold, Srivastava, Pramod K, Tartour, Eric, Valmori, Danila, van der Burg, Sjoerd H, van der Bruggen, Pierre, van den Eynde, Benoît J, Wang, Ena, Zou, Weiping, Whiteside, Theresa L, Speiser, Daniel E, Pardoll, Drew M, Restifo, Nicholas P, and Anderson, Ana C

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, 2.1 Biological and endogenous factors, Aetiology, anergy, anticancer immunity, CD8(+) T cells, cytotoxicity, exhaustion, effector, IFN gamma, senescence, stemness, CD8+ T cells, IFNγ, Oncology and carcinogenesis
Abstract

Whereas preclinical investigations and clinical studies have established that CD8+ T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8+ T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8+ T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8+ T cell immunity, leading to the emergence of dysfunctional CD8+ T cells. The existence of different types of CD8+ T cells in cancer calls for a more precise definition of the CD8+ T cell immune phenotypes in cancer and the abandonment of the generic terms "pro-tumor" and "antitumor." Based on recent studies investigating the functions of CD8+ T cells in cancer, we here propose some guidelines to precisely define the functional states of CD8+ T cells in cancer.

Published
2015

28. Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies

Author

Groeneveldt, Christianne, primary, Kinderman, Priscilla, additional, Griffioen, Lisa, additional, Rensing, Olivia, additional, Labrie, Camilla, additional, van den Wollenberg, Diana J.M., additional, Hoeben, Rob C., additional, Coffey, Matt, additional, Loghmani, Houra, additional, Verdegaal, Els M.E., additional, Welters, Marij J.P., additional, van der Burg, Sjoerd H., additional, van Hall, Thorbald, additional, and van Montfoort, Nadine, additional

Published
2024
Full Text
View/download PDF

30. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer

Author

Verdegaal, Els M E, primary, Santegoets, Saskia J, additional, Welters, Marij J P, additional, de Bruin, Linda, additional, Visser, Marten, additional, van der Minne, Caroline E, additional, de Kok, Pita M, additional, Loof, Nikki M, additional, Boekestijn, Sanne, additional, Roozen, Inge, additional, Westra, Inge M, additional, Meij, Pauline, additional, Van der Burg, Sjoerd H, additional, and Kroep, Judith R, additional

Published
2023
Full Text
View/download PDF

31. Delayed vaccine-induced CD8+T cell expansion by topoisomerase I inhibition mediates enhanced CD70-dependent tumor eradication

Author

van der Sluis, Tetje C, primary, van Haften, Floortje J, additional, van Duikeren, Suzanne, additional, Pardieck, Iris N, additional, de Graaf, J Fréderique, additional, Vleeshouwers, Ward, additional, van der Maaden, Koen, additional, Melief, Cornelis J M, additional, van der Burg, Sjoerd H, additional, and Arens, Ramon, additional

Published
2023
Full Text
View/download PDF

35. Defining the Critical Hurdles in Cancer Immunotherapy

Author

Fox, Bernard A, Schendel, Dolores J, Butterfield, Lisa H, Aamdal, Steinar, Allison, James P, Ascierto, Paolo, Atkins, Michael B, Bartunkova, Jirina, Bergmann, Lothar, Berinstein, Neil, Bonorino, Cristina C, Borden, Ernest, Bramson, Jonathan L, Britten, Cedrik M, Cao, Xuetao, Carson, William E, Chang, Alfred E, Characiejus, Dainius, Choudhury, A Raja, Coukos, George, de Gruijl, Tanja, Dillman, Robert O, Dolstra, Harry, Dranoff, Glenn, Durrant, Lindy G, Finke, James H, Galon, Jerome, Gollob, Jared A, Gouttefangeas, Cécile, Grizzi, Fabio, Guida, Michele, Håkansson, Leif, Hege, Kristen, Herberman, Ronald B, Hodi, F Stephen, Hoos, Axel, Huber, Christoph, Hwu, Patrick, Imai, Kohzoh, Jaffee, Elizabeth M, Janetzki, Sylvia, June, Carl H, Kalinski, Pawel, Kaufman, Howard L, Kawakami, Koji, Kawakami, Yutaka, Keilholtz, Ulrich, Khleif, Samir N, Kiessling, Rolf, Kotlan, Beatrix, Kroemer, Guido, Lapointe, Rejean, Levitsky, Hyam I, Lotze, Michael T, Maccalli, Cristina, Maio, Michele, Marschner, Jens-Peter, Mastrangelo, Michael J, Masucci, Giuseppe, Melero, Ignacio, Melief, Cornelius, Murphy, William J, Nelson, Brad, Nicolini, Andrea, Nishimura, Michael I, Odunsi, Kunle, Ohashi, Pamela S, O'Donnell-Tormey, Jill, Old, Lloyd J, Ottensmeier, Christian, Papamichail, Michael, Parmiani, Giorgio, Pawelec, Graham, Proietti, Enrico, Qin, Shukui, Rees, Robert, Ribas, Antoni, Ridolfi, Ruggero, Ritter, Gerd, Rivoltini, Licia, Romero, Pedro J, Salem, Mohamed L, Scheper, Rik J, Seliger, Barbara, Sharma, Padmanee, Shiku, Hiroshi, Singh-Jasuja, Harpreet, Song, Wenru, Straten, Per, Tahara, Hideaki, Tian, Zhigang, van Der Burg, Sjoerd H, von Hoegen, Paul, Wang, Ena, Welters, Marij JP, Winter, Hauke, Withington, Tara, Wolchok, Jedd D, Xiao, Weihua, and Zitvogel, Laurence

Abstract

Abstract Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer.

Published
2011

36. Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma

Author

van den Bulk, Jitske, primary, Verdegaal, Els M.E., primary, van der Ploeg, Manon, primary, Visser, Marten, primary, Nunes, Joana B., primary, de Ru, Arnoud H., primary, Tjokrodirijo, Rayman T.N., primary, Ijsselsteijn, Marieke E., primary, Janssen, Natasja I., primary, van der Breggen, Ruud, primary, de Bruin, Linda, primary, de Kok, Pita, primary, Janssen, George M.C., primary, Ruano, Dina, primary, Kapiteijn, Ellen H.W., primary, van Veelen, Peter A., primary, de Miranda, Noel F.C.C., primary, and van der Burg, Sjoerd H., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Data FS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV+ Men

Author

Gosens, Karien C.M., primary, van der Burg, Sjoerd H., primary, Welters, Marij J.P., primary, Boekestijn, Sanne, primary, Loof, Nikki M., primary, Quint, Wim G.V., primary, van Noesel, Carel J.M., primary, van der Wal, Allard C., primary, Richel, Olivier, primary, Krebber, Wilhelmus J.T.A., primary, Melief, Cornelis J.M., primary, de Vries, Henry J.C., primary, and Prins, Jan M., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Methods S1 from Neoantigen Targetability in Progressive Advanced Melanoma

Author

van den Bulk, Jitske, primary, Verdegaal, Els M.E., primary, van der Ploeg, Manon, primary, Visser, Marten, primary, Nunes, Joana B., primary, de Ru, Arnoud H., primary, Tjokrodirijo, Rayman T.N., primary, Ijsselsteijn, Marieke E., primary, Janssen, Natasja I., primary, van der Breggen, Ruud, primary, de Bruin, Linda, primary, de Kok, Pita, primary, Janssen, George M.C., primary, Ruano, Dina, primary, Kapiteijn, Ellen H.W., primary, van Veelen, Peter A., primary, de Miranda, Noel F.C.C., primary, and van der Burg, Sjoerd H., primary

Published
2023
Full Text
View/download PDF

39. Data from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV+ Men

Author

Gosens, Karien C.M., primary, van der Burg, Sjoerd H., primary, Welters, Marij J.P., primary, Boekestijn, Sanne, primary, Loof, Nikki M., primary, Quint, Wim G.V., primary, van Noesel, Carel J.M., primary, van der Wal, Allard C., primary, Richel, Olivier, primary, Krebber, Wilhelmus J.T.A., primary, Melief, Cornelis J.M., primary, de Vries, Henry J.C., primary, and Prins, Jan M., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Data MS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV+ Men

Author

Gosens, Karien C.M., primary, van der Burg, Sjoerd H., primary, Welters, Marij J.P., primary, Boekestijn, Sanne, primary, Loof, Nikki M., primary, Quint, Wim G.V., primary, van Noesel, Carel J.M., primary, van der Wal, Allard C., primary, Richel, Olivier, primary, Krebber, Wilhelmus J.T.A., primary, Melief, Cornelis J.M., primary, de Vries, Henry J.C., primary, and Prins, Jan M., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure S3 from Neoantigen Targetability in Progressive Advanced Melanoma

Author

van den Bulk, Jitske, primary, Verdegaal, Els M.E., primary, van der Ploeg, Manon, primary, Visser, Marten, primary, Nunes, Joana B., primary, de Ru, Arnoud H., primary, Tjokrodirijo, Rayman T.N., primary, Ijsselsteijn, Marieke E., primary, Janssen, Natasja I., primary, van der Breggen, Ruud, primary, de Bruin, Linda, primary, de Kok, Pita, primary, Janssen, George M.C., primary, Ruano, Dina, primary, Kapiteijn, Ellen H.W., primary, van Veelen, Peter A., primary, de Miranda, Noel F.C.C., primary, and van der Burg, Sjoerd H., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Data TS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV+ Men

Author

Gosens, Karien C.M., primary, van der Burg, Sjoerd H., primary, Welters, Marij J.P., primary, Boekestijn, Sanne, primary, Loof, Nikki M., primary, Quint, Wim G.V., primary, van Noesel, Carel J.M., primary, van der Wal, Allard C., primary, Richel, Olivier, primary, Krebber, Wilhelmus J.T.A., primary, Melief, Cornelis J.M., primary, de Vries, Henry J.C., primary, and Prins, Jan M., primary

Published
2023
Full Text
View/download PDF

43. Data from Neoantigen Targetability in Progressive Advanced Melanoma

Author

van den Bulk, Jitske, primary, Verdegaal, Els M.E., primary, van der Ploeg, Manon, primary, Visser, Marten, primary, Nunes, Joana B., primary, de Ru, Arnoud H., primary, Tjokrodirijo, Rayman T.N., primary, Ijsselsteijn, Marieke E., primary, Janssen, Natasja I., primary, van der Breggen, Ruud, primary, de Bruin, Linda, primary, de Kok, Pita, primary, Janssen, George M.C., primary, Ruano, Dina, primary, Kapiteijn, Ellen H.W., primary, van Veelen, Peter A., primary, de Miranda, Noel F.C.C., primary, and van der Burg, Sjoerd H., primary

Published
2023
Full Text
View/download PDF

45. Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV+ Men

Author

Gosens, Karien C.M., primary, van der Burg, Sjoerd H., additional, Welters, Marij J.P., additional, Boekestijn, Sanne, additional, Loof, Nikki M., additional, Quint, Wim G.V., additional, van Noesel, Carel J.M., additional, van der Wal, Allard C., additional, Richel, Olivier, additional, Krebber, Wilhelmus J.T.A., additional, Melief, Cornelis J.M., additional, de Vries, Henry J.C., additional, and Prins, Jan M., additional

Published
2023
Full Text
View/download PDF

46. Neoantigen Targetability in Progressive Advanced Melanoma

Author

van den Bulk, Jitske, primary, Verdegaal, Els M.E., additional, van der Ploeg, Manon, additional, Visser, Marten, additional, Nunes, Joana B., additional, de Ru, Arnoud H., additional, Tjokrodirijo, Rayman T.N., additional, Ijsselsteijn, Marieke E., additional, Janssen, Natasja I., additional, van der Breggen, Ruud, additional, de Bruin, Linda, additional, de Kok, Pita, additional, Janssen, George M.C., additional, Ruano, Dina, additional, Kapiteijn, Ellen H.W., additional, van Veelen, Peter A., additional, de Miranda, Noel F.C.C., additional, and van der Burg, Sjoerd H., additional

Published
2023
Full Text
View/download PDF

50. Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer.

Author

van Eijck, Casper W. F., Mustafa, Dana A. M., Vadgama, Disha, de Miranda, Noel F. C. C., Koerkamp, Bas Groot, van Tienhoven, Geertjan, van der Burg, Sjoerd H., Malats, Núria, and van Eijck, Casper H. J.

Subjects
RECTAL cancer, PANCREATECTOMY, PANCREATIC surgery, PANCREATIC cancer, PROGNOSIS, CHEMORADIOTHERAPY, GENE expression
Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results